Join community leaders, experts and policy makers to discuss current approaches and challenges to the elimination of viral hepatitis.

Eliminating viral hepatitis in Australia is now possible, with access to testing, treatment and care, and a new, highly effective hepatitis B vaccine.

Hepatitis B and C affects more than 250,000 and 200,000 Australians respectively and are major contributors to deaths caused by liver cancer, liver failure and liver transplantation. Globally, more than 1,000,000 people die from viral hepatitis-related causes each year.

Burnet Institute’s program will address local and global priorities, and build upon ground-breaking biomedical research, modelling and analysis that demonstrates the feasibility and public health benefit of eliminating viral hepatitis.

This year, there will be a particular focus on hepatitis C testing strategies and partnership approaches required to improve care. Burnet will also officially launch its five-year NHMRC-funded program to eliminate hepatitis C in Australia.

Guest speakers will include Burnet Institute’s leading HCV researchers and clinicians, collaborating partners, government and members of the community and affected populations.

FREE event. Registration essential.